Adams Respiratory Therapeutics Inc

Adams Respiratory Therapeutics — Investor Presentation (April 2007)

10 slides from Adams Respiratory Therapeutics's investor presentation, Apr 4, 2007

  1. Slide 1: Closing Remarks

    Mike Valentino Chief Executive Officer Closing Remarks

  2. Slide 2: Safe Harbor

    Safe Harbor This presentation contains certain "forward-looking" statements. These statements are based on the current estimates and assumptions of the management of Adams Respiratory Therapeutics, Inc. ("Adams") as of the date of this presentation and are subject to uncertainty and changes in circu

  3. Slide 3: Key Growth Drivers: OTC Portfolio Diversification and Expansion

    Key Growth Drivers OTC Portfolio Diversification and Expansion

  4. Slide 4: Expansion Accelerates in FY08

    Expansion Accelerates in FY08 Fiscal 2008 For example purposes only.

  5. Slide 5: New Rx NDA - Key Growth Drivers

    OTC Portfolio Diversification and Expansion New Rx NDA - Mucinex with Codeine Key Growth Drivers

  6. Slide 6: New Rx NDA potential sales and TRx share by launch year

    Mucinex with Codeine Potential $9-11 MM $48-55 MM $100-120 MM $160-190 MM $240-280 MM 1-2% 5-6% 10-12% 14-18% 20-23% Launch years will require aggressive promotion to break prescriber habits Once clinical benefits are recognized uptake should be more rapid and steady Note: Percentages represent TRxs

  7. Slide 7: New Rx NDA - Erdosteine Key Growth Drivers

    OTC Portfolio Diversification and Expansion New Rx NDA - Mucinex with Codeine Erdosteine Key Growth Drivers

  8. Slide 8: Where Are We Today?

    Where Are We Today? While subsequent analyses are showing more promising data, it is still too early to determine ultimate outcome Continue 'data mining' during Q4, FY 07 Review results, trends and hypotheses with external experts Formulate potential follow-on research plans in FY08, if warranted Di

  9. Slide 9: Four Catalysts for Growth

    Four Catalysts for Growth OTC Portfolio Diversification and Expansion New Rx NDA - Mucinex with Codeine Erdosteine FDA Exclusivity Decision on DM and D

  10. Slide 10: Mucinex SE, DM and D launch history and Rx market size

    6.7 MM Rx 1.5 MM Rx Consumer Advertising February 2006 Competing Product Removal? Competing Product Removal? FDA Exclusivity Decision Pending Consumer Advertising November 2004 Competing Products Removed December 2003 Launched July 2002 Approved July 2002 $125 MM Rx market $21 MM Rx market Consumer

Adams Respiratory Therapeutics — Investor Presentation (April 2007) on 6ix